{"entity":{"id":"nct06469944","kind":"trial","name":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Sacituzumab tirumotecan, Capecitabine, Fluorouracil (5-FU), Oxaliplatin and Patritumab deruxtecan in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) is a phase 1/2 interventional study registered as NCT06469944 by Merck Sharp & Dohme LLC, with 160 participants planned, started 2024-09-20 and due to reach its primary completion in 2029-09-12. Interventions recorded: Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin and 5-Fluorouracil (5-FU).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06469944","url":"https://clinicaltrials.gov/study/NCT06469944"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","sacituzumab-tirumotecan","capecitabine","fluorouracil","oxaliplatin","patritumab-deruxtecan"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06469944","phase":"1/2","setting":"A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C","sponsor":"Merck Sharp & Dohme LLC","enrolled":160,"outcomes":[]},"route":"/trials/nct06469944/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"},{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}